This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by De León, D. D. Articles by Moshang, T. Search for Related Content PubMed PubMed Citation Articles by De León, D. D. Articles by Moshang, T.

Long-Term (15 Years) Outcome in an Infant with Metastatic Adrenocortical Carcinoma

Divisions of Endocrinology (D.D.D.L., T.M.) and Oncology (B.J.L.), Department of Pediatrics, Children’s Hospital of Philadelphia, Philadelphia, Pennsylvania 19104; and Division of Oncology, Department of Pediatrics, Children’s Memorial Hospital (D.W.), Chicago, Illinois 60614

Address all correspondence and requests for reprints to: Thomas Moshang, M.D., Division of Endocrinology, Room 8416 Main Building, Children’s Hospital of Philadelphia, 34th Street and Civic Center Boulevard, Philadelphia, Pennsylvania 19104-4399. E-mail: moshang{at}chop.edu.

Abstract

Adrenocortical carcinoma is a rare malignancy in children, with a high mortality. Little is known about long-term outcome, especially in infants treated with mitotane. We report the successful long-term outcome of a case of metastatic adrenocortical carcinoma presenting in infancy treated with surgical resection and mitotane. The patient presented at 2 months of age with Cushing’s syndrome, a large adrenal mass, and elevated adrenal steroid levels. The tumor was removed surgically. Intraoperative findings included an adrenal tumor (confirmed malignant pathologically) invading the adrenal vein and vena cava. After surgery he was treated with mitotane at a dose of 2 g/d. Six months after surgery 11-deoxycortisol levels increased, and a computed tomography scan showed a pulmonary metastasis. Mitotane was increased to 2.5 g/d, and the metastasis was removed surgically. Plasma mitotane levels ranged 10–15 µg/ml. Tumor markers remained normal, and mitotane was discontinued at 18 months. During therapy the patient’s somatic growth was poor. His motor and speech development was delayed. After mitotane was discontinued he demonstrated catch-up growth. This case shows successful long-term outcome and recovery from the toxic effects of mitotane.

This article has been cited by other articles:

				I G C Hermsen, H Gelderblom, J Kievit, J A Romijn, and H R Haak Extremely long survival in six patients despite recurrent and metastatic adrenal carcinoma. Eur. J. Endocrinol., June 1, 2008; 158(6): 911 - 919. [Abstract] [Full Text] [PDF]